Key result
Oral PCSK9 inhibitors reduce LDL-C by up to ~60% versus placebo across clinical trials.
Why the study?
Oral PCSK9 inhibitors combine the potency of injectable PCSK9 inhibitors with the convenience of oral administration, but their clinical development and implementation require review.
Do oral PCSK9 inhibitors effectively reduce LDL-C levels?
Comparison
Oral PCSK9 inhibitors (enlicitide and laroprovstat) vs placebo in clinical trials
Design
Review of phase 2 and later clinical development studies
Follow-up
Up to 52 weeks
Authors
Loading...
Oral PCSK9 inhibitors demonstrate significant LDL-C lowering efficacy in early and late-phase trials, offering a convenient alternative to injectable therapies.
Do oral PCSK9 inhibitors effectively reduce LDL-C levels?
Oral PCSK9 inhibitors demonstrate significant LDL-C lowering efficacy in early and late-phase trials, offering a convenient alternative to injectable therapies.
Nguyen et al. (2026) conducted a review in Hyperlipidemia. Oral PCSK9 inhibitors (enlicitide and laroprovstat) vs. Placebo was evaluated. Oral PCSK9 inhibitors enlicitide and laroprovstat achieved placebo-corrected LDL-C reductions of approximately 60% and up to 51%, respectively, in phase 2 and 3 clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: